Business
Vor Bio to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences: TD Cowen Virtual Immunology & Inflammation SummitFireside Chat: Wednesday, November 12, 2025, at 2:30pm ET 8th Annual Evercore Healthcare ConferenceFireside Chat: Tuesday, December 2, 2025, 3:00pm ETLocation: Miami, FL A live webcast and archived replay of
About this update from Vor Biopharma Inc.
[{"type":"image","alt":"Vor Biopharma","displaySize":"","headline":null,"caption":"Vor Biopharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B2LYyFLcnDdgjzJKo4HDhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec","width":300,"height":108}},"lazy":false},{"type":"text","content":"BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor conferences:","length":243,"tagName":"p"},{"type":"text","content":"TD Cowen Virtual Immunology & Inflammation SummitFireside Chat: Wednesday, November 12, 2025, at 2:30pm ET","length":121,"tagName":"p"},{"type":"text","content":"8th Annual Evercore Healthcare ConferenceFireside Chat: Tuesday, December 2, 2025, 3:00pm ETLocation: Miami, FL","length":113,"tagName":"p"},{"type":"text","content":"A live webcast and archived replay of the fireside chats will be available on the investors section of www.vorbio.com.","length":118,"tagName":"p"},{"type":"text","content":"About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.","length":381,"tagName":"p"},{"type":"text","content":"Media & Investor Contacts:Carl [email protected]","length":64,"tagName":"p"},{"type":"text","content":"Sarah [email protected]","length":34,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]